Ceapro appoints Ulrich Kosciessa to board
This article was originally published in Scrip
Executive Summary
Ceapro, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, has appointed international pharmaceutical industry expert Dr Ulrich Kosciessa to its board of directors. Dr Kosciessa has over two decades of research, business development and marketing leadership experience. He is a member of the executive management board of Medac, a global pharmaceutical company with operations in 70 countries, managing director of Medac, and chair of the board of Medac Pharma, a US-based subsidiary of Medac focused on specialty pharmaceuticals for autoimmune diseases and cancer.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.